University of Arkansas, Fayetteville

ScholarWorks@UARK
Chemical Engineering Undergraduate Honors
Theses

Chemical Engineering

5-2015

Separatome of Escherichia Coli Analysis of DEAE
Chromatography as pH of loading changes
Rita E. Tejada Vaprio
University of Arkansas, Fayetteville

Follow this and additional works at: https://scholarworks.uark.edu/cheguht

Citation
Tejada Vaprio, R. E. (2015). Separatome of Escherichia Coli Analysis of DEAE Chromatography as pH of
loading changes. Chemical Engineering Undergraduate Honors Theses Retrieved from
https://scholarworks.uark.edu/cheguht/68

This Thesis is brought to you for free and open access by the Chemical Engineering at ScholarWorks@UARK. It has
been accepted for inclusion in Chemical Engineering Undergraduate Honors Theses by an authorized administrator
of ScholarWorks@UARK. For more information, please contact scholar@uark.edu.

Separatome of Escherichia Coli Analysis of DEAE Chromatography as pH of loading changes.

An Undergraduate Honors College Thesis
in the

Ralph E. Martin Department of Chemical Engineering
College of Engineering
University of Arkansas
Fayetteville, AR

by

Rita Tejada Vaprio

April 30th, 2015

1

Table of Contents
Acknowledgements……………………………………………………………………………….3
Abstract…………………………………………………………………………………………...4
Introduction……………………………………………………………………………………….5
Objective………………………………………………………………………………………….6
Materials and methods……………………………………………………………………………7
Production of extract……………………………………………………………………..7
Preparation of buffers…………………………………………………………………….7
Fast Protein Liquid Chromatography…………………………………………………….8
Preparation of sample for analysis……………………………………………………….8
Protein Identification…………………………………………………………...………...9
Results and discussion……………………………………………………………………………9
References.……………………………………………………………………………………….11

2

Acknowledgements
First of all, I would like to thank Dr. Robert Beitle, for allowing me to work in his lab
and all his help, guidance and support during the different aspects of this project. Also, I would
like to thank Rudra Palash Mukherjee, a graduate student from Chemical Engineering, for my
training in the lab and his extensive assistance during this project. This project was funded by a
grant from the University of Arkansas Honors College.

3

Abstract
Recombinant DNA technology is used to produce therapeutics in host organisms and
undergoes several purification steps before it can be used by the end user. Escherichia coli which
has been widely studied has been the microorganism of choice mainly because of its low
production costs. The primary objective of this study was to investigate the optimal conditions to
purify a protein of interest with antifungal properties. Varying the loading pH alters the overall
charge of both the target protein and host cell proteins (HCPs). Identifying genomic proteins that
remain bound regardless of loading pH on DEAE columns will guide future genetic
manipulation to enhance purification without sacrificing product yield. The identity of the
proteins which bind strongly to the DEAE resin even at low pH are important which if nonessential for the growth of E.coli can possibly be deleted to improve column efficiency.
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Introduction
In the recent past the demand for biomolecules and therapeutic proteins has seen a
tremendous growth with the biopharmaceutical market estimated to be worth $99 billion in 2009
[1, 2]. With protein based treatment gaining popularity and replacing chemical based
therapeutics [3], researchers around the world are constantly innovating to facilitate economic
biopharmaceutical production. Recombinant DNA technology is used to produce therapeutics in
host organisms and undergoes several purification steps before it can be used by the end user.
Escherichia coli, which has been widely studied, has been the microorganism of choice mainly
because of its low production costs. Additionally, the physiological and genetic characterization
is already known to researchers which facilitates tailoring the organism to optimally produce the
target proteins of choice. Therapeutics such as insulin, human growth hormone, interleukins etc.
has already been commercially produced in E.coli. [4, 5] The present project focuses on
optimizing downstream purification processes when using E.coli as the host cell as discussed
later.
According to an article on pharmaceutical industry published by the World Health
Organization, about $8 million is spent just on purifying proteins produced recombinantly. Every
extra purification step along with increasing the cost also decreases protein yield with target
protein lost during the procedure. According to a recent study, the fermentation facilities
required for recombinant production of proteins are believed to be nearing full capacity [6]
which makes developing novel techniques to optimize protein purification crucial to meet the
demands of a growing pharmaceutical market. Improvement in fermentation techniques are
being currently widely studied. The present study focuses on overcoming purification challenges
faced during chromatography due to presence of host cell proteins (HCPs).
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E.coli produces numerous proteins in addition to the target protein of interest referred to
as E.coli proteins (ECPs). Presence of ECPs in the final product can adversely affect humans by
stimulating immune responses and should be removed to low levels as detected by a sensitive
analytical method during downstream processing of recombinant protein [7]. The industry
generally employs multiple orthogonal separation steps to reduce HCPs to acceptable level [8].
These steps also helps in removal of other process related impurities such as residual host cell
DNA, and other cell culture components.
The method used for the purification of the E. coli proteins is anion exchange
chromatography with fast liquid protein chromatography (FPLC). FPLC is a high-performance
chromatography that was developed for proteins, aqueous buffer systems, fast flow rates and
availability of stationary phases in most common chromatography modes [10]. This system
makes separation possible because it incorporates high level of automation that includes auto
samplers, gradient program control and peak collection [10].
Objective
The primary objective of this study was to investigate the optimal conditions to purify a
protein of interest with antifungal properties. The studies also aimed to identify the HCPs
produced during mass manufacturing of the target protein should the loading pH on DEAE
columns be changed. Bioreactors were used to mass-produce the protein of interest by fed-batch
techniques. Varying the loading pH alters the overall charge of both the target protein and HCPs,
and identifying genomic proteins which remain bound regardless of loading pH on DEAE
columns will guide future genetic manipulation to enhance purification without sacrificing
product yield.
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Materials and methods
Production of extract
Genetically modified cell lines of MG1655 Escherichia coli containing a plasmid to
produce a fusion protein of antifungal peptide and green fluorescence protein (GFP) was used
which does not bind to the DEAE column at lower pH. The cell pellets of E.Coli were obtained
from Boston Mountain Biotech after fed batch fermentation was performed. Cell pellets were
prepared by centrifuging the harvested culture.
Preparation of buffers
The objective of this project was to vary the pH of the loading buffers of the FPLC in
order to identify proteins that will remain bound regardless of loading pH. For this purpose, two
different pH were chosen. For each pH, two buffer solutions were used for purification in the
following concentrations: for buffer A, 25 M Tris buffer and 1 M NaCl and for buffer B, 25 M
Tris buffer and 5mM of NaCl. The pH was adjusted by adding diluted HCl until the solutions
were pH= 5 and pH=7 for both cases. For the rest of the document, buffers A and B of pH 5 and
pH 7 are referred to as buffer A1, B1 and A2, B2 respectively.
In order to prepare the cell clarified lysate for pH 5 that will be loaded to the 1 mL DEAE
(diethyl amino ethyl) fast flow column from GE Healthcare, 2.5 g of the cell pellets were first
resuspended in 15 mL of buffer A1 and then lysed by sonicating for 15 minutes with a pulse
cycle of 20 seconds with 10 seconds rest. The cell lysate was then centrifuged for 90 minutes at
4000 rpm. The supernatant was decanted carefully which comprised the clarified cell lysate. Cell
pellets and clarified cell lysates when not being used were always frozen at -20°C between
intermediate steps.
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Fast Protein Liquid Chromatography
The samples that were loaded into the chromatography column were prepared by mixing
3 mL of the clarified lysate with 12 mL of buffer A1. A step wise gradient was used using buffer
A1 and buffer B1. Buffer B1 was increased 20% for every 10 column volumes. This means that
the 1 mL DEAE column was subjected to an incremental change of 0.2 M NaCl every 10 mL of
flow volume after the step wise elution gradient had started. Peak fractionation was used to
collect the eluted proteins with 3 mL samples and were then stored at -20°C. This exact same
process was repeated for the protein purification with buffers A2 and B2 for pH 7.
Preparation of sample for analysis
Two of the FPLC runs for each pH, in which similar results were obtained, were selected
for analysis and both sample fractions were combined. For pH 5, the peak corresponding to
fraction 29 (as seen on figure 1) eluted at 85% buffer B was selected to be analyzed. For pH 7,
the peak corresponding to fraction 25 (as seen on figure 2) eluted at 80% buffer B was selected
to be analyzed because it was at the highest salt concentration. Amicon Ultra 0.5 mL
microcentrifugal filters of 3 kDa MWCO were used to concentrate the samples. First, 400 µL of
the selected samples from the FPLC runs with pH 5 and pH 7 were poured into the
microcentrifuge tube using a pipette. Following this, the sample was centrifuged for 10 minutes
at 10,000 rcf three times until it was concentrated to 50 µL. In order to make the sample more
diluted, deionized water was added until it reached a volume of 400 µL. The previous steps were
repeated two more times in order to reach the desired concentration (5 µg in 50 µL) to meet the
requirements for protein characterization. The filtrate was collected and stored at -20°C.
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Protein Identification
The proteins produced by the E. coli were sent for characterization to the Proteomics
Core Facility at University of Arkansas for Medical Sciences (UAMS), a facility that provides
the service of protein characterization by mass spectrometry. Using the information from the
databases Ecogene and Ecocyc, six or seven proteins will be classified as essential or nonessential.
Results and Discussion
The FPLC uses different detectors that are used to follow the progress of the purification.
To detect the proteins, multiple wavelength absorbance detectors are used. These chromatograms
were obtained using the UNICORN Control Software in the ÄKTA chromatography system. As
is evident from the chromatogram shown in Figure 1, there are multiple proteins that bind to

Figure 1: ÄKTA fast protein liquid chromatography chromatogram for pH=5.
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the weak anion exchanger DEAE resin even at low pH. Since GFP has a pI of 6.2, it has a net
positive charge at a pH of 5 and binds weakly to DEAE. For this project, the identity of the
proteins which bind strongly to the DEAE resin even at low pH are important which if nonessential for the growth of E.coli can possibly be deleted to improve column efficiency. There is
a large peak eluted at 0.8 M NaCl concentration (corresponding to fraction 23-27) and a
comparatively smaller peak at 1M NaCl (fraction 29). For purification runs at pH 7, a small
peak was eluted at 0.8 M NaCl (fraction 25). Samples from these fractions (number 29 for pH 5,
and number 25 for pH 7), were sent for protein identification to University of Arkansas for
Medical Sciences Proteomics Core facility. The identity of the proteins shall help to determine if
they are essential to the E. coli, which will direct further studies.

Figure 2: ÄKTA fast protein liquid chromatography chromatogram for pH=7.
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